E-Set MD 4 Tablet contains Ondansetron 4 mg, a selective 5-HT3 receptor antagonist used primarily for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery. Ondansetron works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting, at the 5-HT3 receptors located centrally in the chemoreceptor trigger zone and peripherally in the gastrointestinal tract. This medication is indicated for patients undergoing cancer treatment to reduce the incidence and severity of emesis, thereby improving patient comfort and compliance with therapy. E-Set MD 4 Tablet is administered orally, with dosage and duration tailored according to the clinical scenario and patient response. It is generally well tolerated, with common adverse effects including headache, constipation, and dizziness. Caution is advised in patients with known hypersensitivity to ondansetron or other selective 5-HT3 antagonists, and in those with hepatic impairment or a history of cardiac arrhythmias, as ondansetron may prolong the QT interval. E-Set MD 4 Tablet should be used under medical supervision, with adherence to prescribed dosing to ensure optimal efficacy and safety.